This week, AmSpa CEO, Alex R. Thiersch, JD, speaks with Patrick O’Brien, JD, of AmSpa and ByrdAdatto, to discuss the legal concerns with compounded semaglutide and its name-brand drugs. They talk about the basic legal implications of Ozempic and recent lawsuits, compounding pharmacy issues and general guidelines for navigating this area of the law. Their conversation includes:
Read more about the ongoing lawsuits filed by Novo Nordisk, maker of Ozempic and Wegovy, at the AmSpa Now blog. Stay tuned for new updates on the subject as more info becomes available.
This episode of Medical Spa Insider is sponsored by RepeatMD. Visit https://www.repeatmd.com/ to learn more!
Re-Opening Toolkit for Medical Spas
Aesthetic Injector Compensation and Recruiting
Weekly PPP Update: Program Refunded, Loan Forgiveness Details, and Beginning to Re-open
AmSpa After Hours with Botox Josh
How Do You Show Leadership in Crisis?
Additional PPP and COVID-19 Updates for April 21, 2020
8 Keys to a Successful Medical Spa: AmSpa Virtual Boot Camp
PPP Progress and Other COVID-19 Updates
How to Make $15,000 Per Day in Injectables
The CARES Stimulus and Med Spas, MSOs, and Independent Contractors
Generating Income While Closed Due to Coronavirus
Applying for Emergency Funding Under the Payment Protection Program (PPP)
A Conversation With Allergan
How To Get Relief From Stress and Anxiety During This Difficult Time
Business Strategies to Cope with COVID-19
Managing Cash Flow Amid the COVID-19 Crisis
COVID-19 Crisis: Not Business as Usual
Coronavirus and Your Practice: An HR Perspective
Coronavirus and Your Practice: A Medical Perspective
What Recent Arrests Mean for the Medical Spa Industry—Live from The Medical Spa Show 2020
Create your
podcast in
minutes
It is Free
The Everyday Millionaire
Pure Hustle Podcast
Making Bank
The Prof G Pod with Scott Galloway
Habits and Hustle